EA201391131A1 - Сочетания с мацитентаном для лечения полиморфной глиобластомы - Google Patents

Сочетания с мацитентаном для лечения полиморфной глиобластомы

Info

Publication number
EA201391131A1
EA201391131A1 EA201391131A EA201391131A EA201391131A1 EA 201391131 A1 EA201391131 A1 EA 201391131A1 EA 201391131 A EA201391131 A EA 201391131A EA 201391131 A EA201391131 A EA 201391131A EA 201391131 A1 EA201391131 A1 EA 201391131A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
mattientan
gliooblastomes
polymorphic
combinations
Prior art date
Application number
EA201391131A
Other languages
English (en)
Inventor
Урс Регенасс
Original Assignee
Актелион Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45787254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391131(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Актелион Фармасьютикалз Лтд. filed Critical Актелион Фармасьютикалз Лтд.
Publication of EA201391131A1 publication Critical patent/EA201391131A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к применению мацитентана в сочетании с цитотоксическим химиотерапевтическим агентом (таким как темозоломид или паклитаксел), с лучевой терапией, или с цитотоксическим химиотерапевтическим агентом и с лучевой терапией, для лечения злокачественной глиомы, в частности полиморфной глиобластомы.
EA201391131A 2011-02-04 2012-02-03 Сочетания с мацитентаном для лечения полиморфной глиобластомы EA201391131A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050494 2011-02-04
PCT/IB2012/050513 WO2012104822A1 (en) 2011-02-04 2012-02-03 Combinations comprising macitentan for the treatment of glioblastoma multiforme

Publications (1)

Publication Number Publication Date
EA201391131A1 true EA201391131A1 (ru) 2013-12-30

Family

ID=45787254

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391131A EA201391131A1 (ru) 2011-02-04 2012-02-03 Сочетания с мацитентаном для лечения полиморфной глиобластомы

Country Status (20)

Country Link
US (1) US20130310407A1 (ru)
EP (2) EP2670405B1 (ru)
JP (2) JP5642892B2 (ru)
KR (1) KR101563069B1 (ru)
CN (1) CN103327975A (ru)
AR (1) AR085132A1 (ru)
AU (1) AU2012213036A1 (ru)
BR (1) BR112013019680A2 (ru)
CA (1) CA2823994A1 (ru)
CL (1) CL2013002193A1 (ru)
CO (1) CO6761366A2 (ru)
EA (1) EA201391131A1 (ru)
IL (1) IL227747A0 (ru)
MA (1) MA34952B1 (ru)
MX (1) MX2013008798A (ru)
SG (1) SG192600A1 (ru)
TN (1) TN2013000333A1 (ru)
TW (1) TW201309298A (ru)
WO (1) WO2012104822A1 (ru)
ZA (1) ZA201306613B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
NZ598078A (en) 2009-08-10 2013-07-26 Univ Texas Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy
CN103397308A (zh) * 2013-08-01 2013-11-20 光垒光电科技（上海）有限公司 用于mocvd设备的喷淋头
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
KR101701619B1 (ko) 2015-06-26 2017-02-01 건양대학교산학협력단 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물
KR102574253B1 (ko) 2020-12-15 2023-09-07 주식회사 시선테라퓨틱스 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물
CN115317604B (zh) * 2022-08-11 2023-09-22 南京脑科医院 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116237B8 (pt) * 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
TWI441639B (zh) 2008-02-20 2014-06-21 Actelion Pharmaceuticals Ltd 用於治療卵巢癌之包含紫杉醇之組合
NZ598078A (en) * 2009-08-10 2013-07-26 Univ Texas Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy

Also Published As

Publication number Publication date
TW201309298A (zh) 2013-03-01
ZA201306613B (en) 2015-04-29
JP2014504636A (ja) 2014-02-24
CA2823994A1 (en) 2012-08-09
MX2013008798A (es) 2013-10-17
AU2012213036A1 (en) 2013-09-19
CN103327975A (zh) 2013-09-25
SG192600A1 (en) 2013-09-30
KR101563069B1 (ko) 2015-10-23
WO2012104822A1 (en) 2012-08-09
NZ615005A (en) 2015-10-30
EP2965757A1 (en) 2016-01-13
KR20130118981A (ko) 2013-10-30
BR112013019680A2 (pt) 2016-10-11
AR085132A1 (es) 2013-09-11
CO6761366A2 (es) 2013-09-30
TN2013000333A1 (en) 2015-01-20
CL2013002193A1 (es) 2014-05-09
US20130310407A1 (en) 2013-11-21
EP2670405B1 (en) 2015-09-02
EP2670405A1 (en) 2013-12-11
JP5642892B2 (ja) 2014-12-17
IL227747A0 (en) 2013-09-30
JP2015057409A (ja) 2015-03-26
MA34952B1 (fr) 2014-03-01

Similar Documents

Publication Publication Date Title
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201400178A1 (ru) Лечение рака молочной железы
EA201171367A1 (ru) Винилиндазолильные соединения
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
MX2016002974A (es) Eteres de arilo y sus usos.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
EA201391131A1 (ru) Сочетания с мацитентаном для лечения полиморфной глиобластомы
DK3791896T5 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
CL2013001009A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
EA201591024A1 (ru) Димерные соединения
PH12015501038A1 (en) Inhibitors of iap
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
CR20150148A (es) Azaindolinas
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
CL2014002076A1 (es) Compuestos derivados de oxazolidin-2-ona; composicion y combinacion farmaceutica y uso de los mismos como inhibidores p13k en el tratamiento del cancer.